Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236988 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT02236988: Completed Phase 1 study, sponsored by Amgen.
NCT02236988 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02236988, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will assess up to 12 different oral formulations of apremilast to determine how much apremilast is absorbed by the body compared to a reference formulation.
Primary Outcome
Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.
Interventions
- DRUG Apremilast Immediate Release
- DRUG Apremilast Modified Release 1
- DRUG Apremilast Modified Release 2
- DRUG Apremilast Modified Release 3
- DRUG Apremilast Modified Release 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-01-07 |
| Est. Completion | 2014-09-11 |
| Phase | Phase 1 |
What the finished NCT02236988 record still lists
NCT02236988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 5 interventions - of which Apremilast Immediate Release is the first listed.
NCT02236988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02236988 about?
NCT02236988 is a clinical study titled "Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men". This study will assess up to 12 different oral formulations of apremilast to determine how much apremilast is absorbed by the body compared to a reference formulation.
What is the current status of trial NCT02236988?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-01-07. Estimated completion is 2014-09-11.
What interventions are being tested in trial NCT02236988?
The interventions under investigation include: Apremilast Immediate Release (DRUG), Apremilast Modified Release 1 (DRUG), Apremilast Modified Release 2 (DRUG), Apremilast Modified Release 3 (DRUG), Apremilast Modified Release 4 (DRUG).
Who is sponsoring clinical trial NCT02236988?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02236988's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI